A Randomized, Double-blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects.

Trial Profile

A Randomized, Double-blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2013

At a glance

  • Drugs MGL-3196 (Primary)
  • Indications Dyslipidaemias; Hypercholesterolaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Apr 2013 Results discussed in a First Times Disclosures session at National Meeting of the American Chemical Society.
    • 29 Nov 2012 Status changed from recruiting to completed.
    • 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top